Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Theriva Biologics, Inc. (SYN)
|
Add to portfolio |
|
|
|
| Price: |
$0.60
| | Metrics |
| OS: |
17.0
|
M
| |
|
|
| Market cap: |
$10.2
|
M
| |
|
|
|
Net cash:
|
$34
|
M
| |
$2.00
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 39.9 | 41.4 | 20.8 |
| Revenue growth | | | | | -100.0% | -3.6% | 99.1% | 55.9% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 39.9 | 41.4 | 20.8 |
| Gross margin | | | | | | 100.0% | 100.0% | 100.0% |
| Research and development | 7.8 | 5.1 | 11.1 | 11.8 | 18.8 | 29.1 | 32.9 | 14.5 |
| General and administrative | 6.5 | 5.0 | 4.6 | 5.7 | 7.5 | 10.1 | 8.1 | 6.0 |
| EBIT | -14.3 | -10.2 | -15.7 | -17.6 | -26.3 | -38.6 | -40.6 | -20.2 |
| EBIT margin | | | | | | -96.8% | -98.0% | -97.2% |
| Pre-tax income | -14.3 | -10.1 | -15.4 | -13.4 | -15.5 | -27.8 | -44.8 | -19.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.3% | 0.0% |
| Net income | -23.2 | -12.6 | -16.1 | -25.3 | -22.1 | -27.3 | -43.7 | -19.8 |
| Net margin | | | | | | -68.3% | -105.6% | -95.1% |
| |
| Diluted EPS | ($0.19) | ($0.66) | ($0.98) | ($4.06) | ($6.23) | ($0.29) | ($0.54) | ($0.32) |
| Shares outstanding (diluted) | 121.9 | 19.0 | 16.4 | 6.2 | 3.6 | 94.3 | 80.7 | 61.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|